CT-XEROX
15.6.2020 14:02:09 CEST | Business Wire | Press release
A new global business survey commissioned by Xerox Holdings Corporation (NYSE:XRX) shows an estimated 82% of the workforce in respondents’ organizations will have returned to the workplace in 12-18 months’ time, on average. In preparation for a return, companies are investing in new resources to support a hybrid remote / in-office workforce, with 56% increasing technology budgets and 34% planning to speed their digital transformation as a result of COVID-19.
The Xerox Future of Work Survey, conducted by the independent research firm Vanson Bourne, polled 600 IT decision makers including senior C-level professionals from the U.S., Canada, the U.K., Germany and France, whose organizations have at least 500 employees. Respondents reported challenges caused by the sudden transition to remote work, with 72% citing they were not fully prepared from a technology perspective. In addition to technology (29%), the biggest pain points during the required work from home period were communication breakdown across teams/employees (26%) and maintaining focus (25%).
“While there is no doubt the COVID-19 pandemic has changed the way we work, our research found that over time many companies plan to have most employees back in an office environment. This could be for a variety of reasons, including communication, speed of decision-making and talent development,” said Steve Bandrowczak, Xerox president and chief operations officer. “At the same time, the sudden shutdown and ongoing hybrid work environment has exposed technology gaps that require new or additional investment in the coming months.”
Key survey findings and Xerox takeaways include:
-
Businesses plan to return most employees to the office, though expanded remote work policies are here to stay.
Prior to work from home requirements being imposed, 33% of respondents said network/data security and privacy was their biggest concern with a remote workforce; 24% cited employee productivity followed by 16% citing technology infrastructure. These concerns, coupled with the belief held by 95% of respondents that in-person communication is important for personal development and assessing talent, indicate widespread remote work will not replace more traditional workspaces.
However, now that businesses are more comfortable with remote work, attitudes and policies of C-suite leaders and IT decision makers are shifting. Among the countries polled, the U.S. is the most likely to have an increase in confidence in remote working (86%), followed by the U.K. (80%), Germany (80%), Canada (77%), and France (75%). Furthermore, 58% plan to change their work from home policy within the next year, highlighting the need for companies to support a hybrid workforce.
Our takeaway: Employees may not be going back to the office all at once — or even in the same capacity as before — but the need for organizations to support a hybrid workforce is here for the foreseeable future.
-
Sudden stay-at-home orders quickly revealed technology gaps.
The rapid transition to remote work was difficult for most businesses, with only 28% saying they were fully prepared and 29% citing technology as their biggest pain point. Among the specific countries polled, France was the least likely to be fully prepared for the sudden transition to remote work, while the U.S. was the most likely to be fully prepared. With regards to technology specifically, respondents said their top challenges were remote IT support (35%), inadequate workflow solutions (27%), lack of communications and collaboration tools (22%) and lack of cloud-based solutions (10%). 85% of business leaders also missed the accessibility and ease of use of their office printers, with U.S. respondents missing them the most (93%) followed by Germany (92%) and France (91%).
Our takeaway : To mitigate against future disruptions, such as the rapid transition to remote work resulting from COVID-19, companies will look to invest in new technologies and seek added capability from existing tools to accelerate their processes digital transformation.
-
Technology purchasing priorities are shifting to better support employees.
As a result of technology gaps uncovered by having a mostly remote workforce, 70% of IT decision makers globally are reevaluating their budget spend, with companies increasing investment in remote technology resources (55%) or a hybrid of remote and in-office resources (40%). The pandemic also has businesses prioritizing investments in cloud-based software (65%), remote IT (63%) support and collaboration software (52%).
Hardware such as laptops and printers were another important consideration, especially for companies based in France, with 22% of respondents citing it as the most important need when it comes to technology, productivity and their overall work experience.
Our Takeaway : COVID-19 is feeding digital transformation plans and companies are placing a renewed focus on meeting employees’ needs with both hardware and software.
For more information, visit www.Xerox.com/MakeNowWork .
Methodology
The survey of 600 respondents located in the U.S., Canada, U.K., Germany and France was conducted by independent research firm Vanson Bourne in May 2020. Respondents included IT decision makers (including senior C-level professionals), all from organizations with at least 500 employees across a range of sectors, including business and professional services, retail, health care, financial services, and travel and hospitality.
About Xerox
Xerox Holdings Corporation makes every day work better. We are a workplace technology company building and integrating software and hardware for enterprises large and small. As customers seek to manage information across digital and physical platforms, Xerox delivers a seamless, secure and sustainable experience. Whether inventing the copier, Ethernet, the laser printer or more, Xerox has long defined the modern work experience. Learn how that innovation continues at xerox.com .
Note: To receive RSS news feeds, visit https://www.news.xerox.com . For open commentary, industry perspectives and views, visit http://twitter.com/xerox , http://www.facebook.com/XeroxCorp , https://www.instagram.com/xerox/ , http://www.linkedin.com/company/xerox , http://www.youtube.com/XeroxCorp .
Xerox® is a trademark of Xerox Corporation in the United States and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005365/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
